Tags: Drug.
Talimogene laherparepvec (tal im’ oh jeen la her pa rep’ vek) often simply called T-VEC is a cancer-killing (oncolytic) virus currently being studied for the treatment of melanoma and other advanced cancers. The drug was initially developed by BioVex Inc. under the name OncoVEXGM-CSF until it was acquired by Amgen in 2011. With the announcement of positive results in March 2013 T-VEC is the first oncolytic virus to be proven effective in a Phase III clinical trial.
